There are reports of higher incidences of discontinuing ICI treatment because of significant hepatotoxicity in patients receiving sunitinib or pazopanib with nivolumab for treatment of renal cell carcinoma (RCC) [38] and using ipilimumab with BRAF inhibitors for treatment of melanoma [39]. Here, BRAF is linked to melanoma.